The Latest Decentralized Clinical Trials Industry Statistics Explained
By 2026, Decentralized Clinical Trials (DCTs) market is anticipated to reach around USD 13 billion globally.
The statistic “By 2026, Decentralized Clinical Trials (DCTs) market is anticipated to reach around USD 13 billion globally” suggests that the market for Decentralized Clinical Trials is expected to significantly grow and expand over the coming years. This growth trajectory reflects the increasing demand for more efficient and patient-centric approaches to conducting clinical trials. Decentralized Clinical Trials offer the advantage of remote participation, leveraging technology and innovative methods to streamline the trial process and enhance patient engagement. The projected USD 13 billion market value by 2026 indicates a shift towards decentralized and virtual trial models, with potential benefits for both patients and researchers in the clinical trial ecosystem.
According to estimates, DCTs could cut down recruitment time by more than 30%.
The statistic “According to estimates, DCTs could cut down recruitment time by more than 30%” suggests that utilizing Direct Contracting Technologies (DCTs) in the recruitment process could lead to a significant reduction in the time it takes to hire new employees. This estimate indicates that implementing DCTs may streamline and expedite recruitment processes, potentially saving organizations time and resources. By leveraging technology to enhance various stages of recruitment, such as candidate sourcing, screening, and communication, companies can efficiently identify and onboard suitable candidates faster, leading to increased productivity and efficiency in the hiring process.
Almost 70% of potential participants live more than two hours away from the nearest study center, making the adoption of decentralization signification.
The statistic indicates that nearly 70% of potential participants are located at a distance of over two hours from the nearest study center. This distance poses a significant challenge for these individuals to physically attend the study center, potentially leading to recruitment difficulties and reduced participation rates. In response to this geographical barrier, the adoption of decentralization in research, wherein study activities are conducted closer to participants’ locations or remotely, becomes crucial. Decentralization can help overcome logistical challenges, improve accessibility for participants, and ultimately enhance the inclusivity and effectiveness of research studies by expanding recruitment opportunities beyond the proximity of traditional study centers.
The number of trials registered on clinicaltrials.gov using terms “decentralized,” “virtual,” “remote,” or “siteless” increased by 145% year over year in May 2020.
The statistic indicates that in May 2020, there was a significant increase of 145% in the number of registered trials on clinicaltrials.gov that utilized terms such as “decentralized,” “virtual,” “remote,” or “siteless” compared to the previous year. This suggests a growing trend in the adoption of decentralized and remote approaches within clinical trial settings. Such methods are becoming increasingly popular as they offer more flexible and convenient options for conducting trials, particularly in light of the challenges posed by the COVID-19 pandemic. The notable surge in the number of trials adopting these innovative approaches highlights the shift towards more efficient and patient-centric clinical trial practices.
Phase III stage trials comprised over 50.5% of decentralized clinical trials in 2020.
The statistic suggests that a significant majority, specifically over 50.5%, of decentralized clinical trials conducted in 2020 were in the Phase III stage. Phase III trials are typically the final stage in testing new drugs or treatments before seeking approval for market release, making them crucial in determining the efficacy and safety of the intervention. The high proportion of Phase III trials in decentralized settings indicates a growing trend in leveraging technology and remote monitoring to conduct clinical research, potentially offering more flexible and patient-friendly options while maintaining the rigor and reliability of traditional trial protocols.
A dedicated app can reportedly reduce trial drop-out rates by as much as 30%.
The statistic suggests that implementing a dedicated application can lead to a significant decrease in the dropout rates observed in clinical trials, with a reported reduction of up to 30%. This indicates that using technology such as a mobile app tailored specifically for the trial could potentially improve participant engagement, adherence to protocols, and overall satisfaction with the study. By providing participants with convenient access to study information, reminders, and communication channels, the app may help to address common issues that contribute to dropouts in clinical trials, ultimately enhancing the quality and reliability of the study results.
As of 2020, North America holds the largest market share for DCTs at 52%.
The statistic indicates that as of 2020, North America has the highest market share for Dual Clutch Transmissions (DCTs) among all regions, accounting for 52% of the total market. This signifies that North America is a significant player in the DCT industry, with a strong presence and dominance in this technology compared to other regions. The data suggests that DCTs are particularly popular and widely adopted in the North American market, potentially due to factors such as consumer demand, regulatory environment, technological advancements, or market trends. This information is valuable for businesses and stakeholders in the automotive industry, helping them understand the market dynamics and opportunities in North America for DCT technologies.
The COVID-19 pandemic has increased the growth rate of DCTs by 50%.
The statistic “The COVID-19 pandemic has increased the growth rate of DCTs by 50%” suggests that during the pandemic, there has been a notable rise in the rate at which Discrete Choice Tasks (DCTs) have been adopted or utilized. DCTs are frequently used in various fields, such as market research and behavioral economics, to understand decision-making processes. The 50% increase in the growth rate of DCTs indicates a significant shift towards the use of these tasks, likely driven by the need for remote data collection methods and a greater reliance on digital tools due to restrictions and safety measures imposed during the pandemic. This statistic highlights the impact of the global health crisis on research methodologies and the adaptation of techniques to suit the changing circumstances.
The percentage of clinical trials incorporating wearable devices increased from 9% in 2015 to 18% in 2020.
The statistic indicates a notable growth in the adoption of wearable devices in clinical trials over a five-year period. In 2015, only 9% of clinical trials were incorporating wearable devices, while by 2020, this figure had doubled to 18%. This significant increase suggests that researchers and healthcare professionals are increasingly recognizing the potential benefits and value of using wearable devices to collect real-time health data and monitor participants during clinical trials. The rise in the use of wearable devices may offer more accurate and continuous data collection, potentially leading to improved study outcomes and insights into various health conditions.
80% of participants reported a preference for telehealth visits over traditional on-site visits.
The statistic indicates that of the participants surveyed, 80% expressed a preference for telehealth visits as opposed to traditional on-site visits for their healthcare needs. This suggests that the majority of the sample population found telehealth services to be more convenient, accessible, and/or preferable compared to in-person visits. This finding implies a potential shift in patient attitudes towards digital healthcare solutions, possibly driven by factors such as convenience, cost-effectiveness, and the ongoing COVID-19 pandemic. Further research and analysis could provide insight into the specific reasons behind this preference and its implications for the healthcare industry.
Oncology was the largest therapeutic area segment for decentralized clinical trials in 2020 and accounted for a share of more than 35%.
In 2020, oncology emerged as the dominant therapeutic area segment for decentralized clinical trials, representing more than 35% of the total share. This statistic indicates that a significant proportion of decentralized clinical trials conducted throughout the year were focused on oncology, highlighting the growing importance and popularity of decentralized approaches within this field. The prominence of oncology in decentralized clinical trials suggests that researchers and pharmaceutical companies are increasingly leveraging technology and remote methodologies to conduct clinical trials for cancer treatments, possibly due to factors such as the need for patient-centric trials, enhanced patient access, and the potential for more efficient and inclusive trial recruitment processes.
Depression has the highest number of decentralized trials with 15, followed by asthma and diabetes with 9, and hypertension with 8.
This statistic indicates the distribution of decentralized clinical trials across different medical conditions, specifically focusing on depression, asthma, diabetes, and hypertension. It shows that depression has been the most common condition studied in decentralized trials, with a total of 15 trials conducted. Asthma and diabetes follow closely behind with 9 trials each, while hypertension has had 8 trials. This information suggests that there is a relatively higher research focus on depression in decentralized trials compared to these other conditions, potentially reflecting the prevalence and impact of depression on individuals’ mental health and well-being. Researchers and policymakers can use this data to prioritize resources and interventions for these specific medical conditions based on the evidence gathered from decentralized trials.
Decentralized trials resulted in a 30% increase in recruitment
The statistic ‘Decentralized trials resulted in a 30% increase in recruitment’ indicates that when clinical trials are conducted using decentralized approaches, such as virtual visits or home monitoring, there was a substantial improvement in participant recruitment rates compared to traditional centralized trial methods. This 30% increase suggests that decentralized trials offer a more convenient and accessible way for individuals to participate in research studies, potentially reaching a more diverse and broader population. By leveraging technology and minimizing barriers related to travel and time commitments, decentralized trials have the potential to enhance recruitment efficiency and contribute to the overall success and generalizability of clinical research studies.
Approximately 40% of DCT solutions are expected to leverage artificial intelligence capabilities by 2025.
The statistic stating that approximately 40% of DCT (Digital Content Transformation) solutions are expected to leverage artificial intelligence capabilities by 2025 suggests a notable trend towards incorporating AI technologies in the domain of digital content management. This projection indicates a significant shift towards automation and intelligent decision-making processes in handling digital content. By harnessing AI capabilities, organizations can streamline content workflows, enhance user experiences, and drive more personalized and targeted content delivery strategies. This statistic underscores the growing importance of AI in optimizing digital content transformation processes and staying competitive in the rapidly evolving digital landscape.
The Asia Pacific region is expected to witness the fastest growth over the forecast period at a CAGR of 18% due to a surge in the geriatric population.
The statistic states that the Asia Pacific region is projected to experience the most rapid growth within the given forecast period, with a Compound Annual Growth Rate (CAGR) of 18%. This growth is attributed to the significant increase in the elderly population within the region. As the number of older individuals rises, there can be a surge in demand for various goods and services catering to this demographic, such as healthcare, pharmaceuticals, and leisure activities. The aging population often leads to increased spending on healthcare and related products, thereby driving economic growth in the Asia Pacific region.
References
0. – https://www.www2.deloitte.com
1. – https://www.www.appliedclinicaltrialsonline.com
2. – https://www.www.reportsanddata.com
3. – https://www.www.clinicalleader.com
4. – https://www.www.researchandmarkets.com
5. – https://www.www.globenewswire.com
6. – https://www.www.outsourcing-pharma.com
7. – https://www.www.ncbi.nlm.nih.gov
8. – https://www.www.frost.com
9. – https://www.www.nature.com
